glp-1 receptor agonist with dpp-4 inhibitor combination not recommended versus and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes DPP-4 INHIBITORS - Dipeptidyl Peptidase-4

[PubMed ID: 25789296]

These come as once a week self-injection medications

Acknowledgments The authors thank the participants of the FIH study

It exhibits bitterness and reduces blood glucose and urinary sugar levels when administered via IV injections of STZ at 40 mg/kg in Wistar rats, demonstrating anti-diabetic effects through GLP-1 receptor activity

Important aspects to be considered are (1) their long half-lives, (2) the capacity of GLP-1 receptor agonism to slow gastric emptying even at physiological GLP-1 concentrations, (c) tachyphylaxis observed with prolonged treatment, and (d) the limited effect on gastric emptying in individuals with slow gastric emptying before initiating treatment